{"id":"NCT00391443","sponsor":"Actelion","briefTitle":"BUILD 3: Bosentan Use in Interstitial Lung Disease","officialTitle":"Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2010-02","completion":"2010-07","firstPosted":"2006-10-24","resultsPosted":"2012-05-25","lastUpdate":"2025-02-04"},"enrollment":616,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Pulmonary Fibrosis"],"interventions":[{"type":"DRUG","name":"Bosentan","otherNames":["Ro 47-0203","ACT-050088"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Bosentan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, event-driven, group sequential, phase III superiority study. The primary objective is to demonstrate that bosentan delays disease worsening or death in patients with Idiopathic Pulmonary Fibrosis.","primaryOutcome":{"measure":"Time to Occurrence of Disease Worsening or Death up to End of Study.","timeFrame":"36 months","effectByArm":[{"arm":"Placebo","deltaMin":10,"sd":null},{"arm":"Bosentan","deltaMin":18,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2110"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":25},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["21474646"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":74,"n":209},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","IDIOPATHIC PULMONARY FIBROSIS","COUGH","DYSPNOEA","BRONCHITIS"]}}